LUMO

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Jim SimonsRenaissance Technologies $-827.5K ExitQ4 2024 $827k -- --
Jefferies GroupInvestor $-466.9K ExitQ4 2024 $467k -- --
Jim SimonsRenaissance Technologies $326.8K AddQ3 2024 $327k -- --
Jefferies GroupInvestor $187.0K AddQ3 2024 $187k -- --
Ken GriffinCitadel Advisors $-43.5K ExitQ3 2024 $43k -- --
Jim SimonsRenaissance Technologies $500.1K AddQ2 2024 $500k -- --

Trade LUMO

About Lumos Pharma, Inc.

Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug candidate is being investigated for its potential in treating pediatric growth hormone deficiency and various other uncommon endocrine conditions. The company's operations are based in Austin, Texas.

CEO: Richard J. Hawkins
IPO Date: Nov 11, 2011

Market Data

Open: $4.33
High: $4.34
Low: $4.33
Volume: 390.9K
Avg Volume: 96.1K
52W High: $4.58
52W Low: $1.37

Valuation

Market Cap: $38M
Enterprise Value: $3.0M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-31M
Revenue: $2.1M
Net Income: $-34M
Cash: $35M
Debt: $585k

Events

EarningsNov 7

EPS est. -0.56 · actual -0.9